Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022;17(1):4-8.
doi: 10.2174/1574887117666211221170344.

An Overview of Combination Treatment with Citicoline in Dementia

Pietro Gareri  1 , Nicola Veronese  2 , Antonino Maria Cotroneo  3
Affiliations

An Overview of Combination Treatment with Citicoline in Dementia

Pietro Gareri et al. Rev Recent Clin Trials. 2022.

Abstract

Introduction: The present article reports an overview of the studies about combination treatment with citicoline of Alzheimer's (AD) and mixed dementia (MD).

Methods: A Medline search was carried out by using the keywords Alzheimer's dementia, mixed dementia, older people, treatment with citicoline, memantine, and acetylcholinesterase inhibitors (AchEIs).

Results: Six studies were found to match the combination treatment of citicoline with AcheIs and/or memantine. The CITIRIVAD and CITICHOLINAGE studies were the first to report the potential benefits of adding citicoline to acetylcholinesterase inhibitors (AchEIs). Then, we added citicoline to memantine in the CITIMEM study, and finally, we demonstrated benefits in terms of delay in cognitive worsening with the triple therapy (citicoline + AchEIs + memantine). Other authors also reinforced our hypothesis through two further studies.

Conclusion: Open, prospective studies are advised to confirm the utility of combination therapy with citicoline for the treatment of AD and MD.

Keywords: Alzheimer’s dementia; Citicoline; cognitive impairment; combination therapy; mixed dementia; older people.

PubMed Disclaimer

MeSH terms